| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tammy L Kindel, Qing Yang, Stephanie M Yoder, Patrick Ts. Nutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar rats. American journal of physiology. Gastrointestinal and liver physiology. vol 296. issue 2. 2009-03-13. PMID:19056762. |
the incretin hormones gastric inhibitory polypeptide (gip) and glucagon-like peptide-1 (glp-1) augment postprandial glucose-mediated insulin release from pancreatic beta-cells. |
2009-03-13 |
2023-08-12 |
rat |
| Cheng-Hao Jin, Su Young Chae, Sohee Son, Tae Hyung Kim, Key An Um, Yu Seok Youn, Seulki Lee, Kang Choon Le. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. Journal of controlled release : official journal of the Controlled Release Society. vol 133. issue 3. 2009-03-05. PMID:18977255. |
these biotinylated exendin-4 analogues preserved glp-1 receptor binding affinity and stimulated insulin secretion in rin-m5f murine insulinoma cells and in isolated rat islets, respectively, and were as potent as exendin-4. |
2009-03-05 |
2023-08-12 |
mouse |
| R Burceli. What is known, new and controversial about GLP-1? Minutes of the 1st European GLP-1 Club Meeting, Marseille, 28-29 May 2008. Diabetes & metabolism. vol 34. issue 6 Pt 1. 2009-02-26. PMID:19026584. |
whereas the theoretical benefit of insulin is based on normalization of functional physiology, therapeutic strategies based on glp-1 aim to increase the circulating concentration of a natural component--the hormone glp-1. |
2009-02-26 |
2023-08-12 |
human |
| J Girar. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes & metabolism. vol 34. issue 6 Pt 1. 2009-02-26. PMID:19036624. |
gip and glp-1 stimulate insulin biosynthesis and insulin secretion in a glucose-dependent manner. |
2009-02-26 |
2023-08-12 |
Not clear |
| Jens Juul Holst, Tina Vilsbøll, Carolyn F Deaco. The incretin system and its role in type 2 diabetes mellitus. Molecular and cellular endocrinology. vol 297. issue 1-2. 2009-02-25. PMID:18786605. |
the impaired action of glp-1 and gip in t2dm may be at least partly restored by improved glycaemic control, as shown in studies involving 4 weeks of intensive insulin therapy. |
2009-02-25 |
2023-08-12 |
human |
| Jens Juul Holst, Tina Vilsbøll, Carolyn F Deaco. The incretin system and its role in type 2 diabetes mellitus. Molecular and cellular endocrinology. vol 297. issue 1-2. 2009-02-25. PMID:18786605. |
the reduced incretin effect is believed to contribute to impaired regulation of insulin and glucagon secretion in t2dm, and, in support of this, exogenous glp-1 administration may restore blood glucose regulation to near normal levels. |
2009-02-25 |
2023-08-12 |
human |
| Angelo Avogar. [Glucagon-like peptide-1: pleiotropic effects on the cardiovascular system]. Giornale italiano di cardiologia (2006). vol 9. issue 11. 2009-02-25. PMID:19058666. |
the main actions of glp-1 are: 1) to stimulate insulin secretion; 2) to inhibit glucagon secretion; 3) to slow gastric emptying; 4) to stimulate the neogenesis of insulin secreting cells. |
2009-02-25 |
2023-08-12 |
Not clear |
| A J Schee. New therapeutic approaches in type 2 diabetes. Acta clinica Belgica. vol 63. issue 6. 2009-02-24. PMID:19170358. |
besides classical sulfonylureas and glinides, new insulin secretagogues are now available, which target the incretin gut hormone glucagon-like peptide-1 (glp-1). |
2009-02-24 |
2023-08-12 |
Not clear |
| A J Schee. New therapeutic approaches in type 2 diabetes. Acta clinica Belgica. vol 63. issue 6. 2009-02-24. PMID:19170358. |
indeed, oral incretin enhancers acting as antagonists of the enzyme dpp-4 (dipeptidylpeptidase-4), which inactivates natural glp-1,and injectable incretin mimetics (exenatide) or analogues (liraglutide), which reproduce the actions of glp-1 while resisting to dpp-4, represent new opportunities to stimulate insulin secretion, without increasing the risk of hypoglycaemia and weight gain. |
2009-02-24 |
2023-08-12 |
Not clear |
| Cedrick D Dotson, Lan Zhang, Hong Xu, Yu-Kyong Shin, Stephan Vigues, Sandra H Ott, Amanda E T Elson, Hyun Jin Choi, Hillary Shaw, Josephine M Egan, Braxton D Mitchell, Xiaodong Li, Nanette I Steinle, Steven D Munge. Bitter taste receptors influence glucose homeostasis. PloS one. vol 3. issue 12. 2009-02-23. PMID:19092995. |
for example, sweeteners stimulate taste receptors on the surface of gut enteroendocrine l cells to elicit an increase in intracellular ca(2+) and secretion of the incretin hormone glucagon-like peptide-1 (glp-1), an important modulator of insulin biosynthesis and secretion. |
2009-02-23 |
2023-08-12 |
Not clear |
| Gareth E Lim, Guan J Huang, Nina Flora, Derek LeRoith, Christopher J Rhodes, Patricia L Brubake. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. vol 150. issue 2. 2009-02-20. PMID:18818290. |
insulin resistance and type 2 diabetes mellitus are associated with impaired postprandial secretion of glucagon-like peptide-1 (glp-1), a potent insulinotropic hormone. |
2009-02-20 |
2023-08-12 |
mouse |
| Gareth E Lim, Guan J Huang, Nina Flora, Derek LeRoith, Christopher J Rhodes, Patricia L Brubake. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. vol 150. issue 2. 2009-02-20. PMID:18818290. |
we therefore hypothesized that the l cell is responsive to insulin and that insulin resistance impairs glp-1 secretion. |
2009-02-20 |
2023-08-12 |
mouse |
| Gareth E Lim, Guan J Huang, Nina Flora, Derek LeRoith, Christopher J Rhodes, Patricia L Brubake. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. vol 150. issue 2. 2009-02-20. PMID:18818290. |
in all cells, insulin activated the phosphatidylinositol 3 kinase-akt and mapk kinase (mek)-erk1/2 pathways and stimulated glp-1 secretion by up to 275 +/- 58%. |
2009-02-20 |
2023-08-12 |
mouse |
| Gareth E Lim, Guan J Huang, Nina Flora, Derek LeRoith, Christopher J Rhodes, Patricia L Brubake. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. vol 150. issue 2. 2009-02-20. PMID:18818290. |
these findings indicate that the intestinal l cell is responsive to insulin and that insulin resistance in vitro and in vivo is associated with impaired glp-1 secretion. |
2009-02-20 |
2023-08-12 |
mouse |
| Janet B McGil. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgraduate medicine. vol 121. issue 1. 2009-02-19. PMID:19179813. |
insulin, glucagon, amylin, the incretin hormones glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), and other hormones and enzymes interact to maintain glucose homeostasis and normal cellular metabolism. |
2009-02-19 |
2023-08-12 |
Not clear |
| Andrew A Palladino, Samir Sayed, Lorraine E Levitt Katz, Paul R Gallagher, Diva D De Leó. Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication. The Journal of clinical endocrinology and metabolism. vol 94. issue 1. 2009-02-12. PMID:18957502. |
we hypothesize that increased glucagon-like peptide-1 (glp-1) secretion contributes to the exaggerated insulin surge and plays a role in the pathophysiology of this disorder. |
2009-02-12 |
2023-08-12 |
Not clear |
| Bo Ahré. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert opinion on emerging drugs. vol 13. issue 4. 2009-02-12. PMID:19046129. |
this increases circulating levels of active glp-1, stimulates insulin secretion and inhibits glucagon secretion, resulting in lowering of glucose levels and improvement of glycemic control in patients with type 2 diabetes. |
2009-02-12 |
2023-08-12 |
human |
| Wook Kim, Josephine M Ega. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacological reviews. vol 60. issue 4. 2009-02-12. PMID:19074620. |
glp-1, on the other hand, is still insulinotropic in t2dm, and this has led to the development of compounds that activate the glp-1 receptor with a view to improving insulin secretion. |
2009-02-12 |
2023-08-12 |
Not clear |
| Mariko Morishita, Tomohiro Tanaka, Takayuki Shida, Kozo Takayam. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. Journal of controlled release : official journal of the Controlled Release Society. vol 132. issue 2. 2009-02-11. PMID:18804128. |
the aim of this study was to evaluate the effects of the long-chain polyunsaturated fatty acids docosahexaenoic acid (dha) and eicosapentaenoic acid (epa) on blood glucose levels, plasma insulin, and glp-1 concentrations. |
2009-02-11 |
2023-08-12 |
mouse |
| Mariko Morishita, Tomohiro Tanaka, Takayuki Shida, Kozo Takayam. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. Journal of controlled release : official journal of the Controlled Release Society. vol 132. issue 2. 2009-02-11. PMID:18804128. |
after an intraperitoneal glucose challenge, marked endogenous glp-1 secretion, substantial insulin release and subsequent glucose reductions were observed in the intracolonic dha and epa treatment groups. |
2009-02-11 |
2023-08-12 |
mouse |